1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E244C0E8624B0D5E00258ADA0025F0EA
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-rare-disease-field-medical-excellence-apac-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Rare Disease Field Medical Excellence in APAC: Establishing Standards for High Performance & Impact

ID: 5797


Features:

9 Info Graphics

14 Data Graphics

110+ Metrics

7 Narratives


Pages/Slides: 28


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Rare Disease Field Medical Excellence in APAC: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

The rare disease market in the Asia-Pacific (APAC) region is characterized by unique challenges related to diverse patient populations, regulatory environments, and access to specialized care. To thrive in this dynamic landscape, optimizing the efficiency of field medical teams is essential.

Best Practices, LLC undertook this benchmarking research to establish standards for high field medical performance and impact in APAC's rare disease market. By establishing effective MSL performance metrics, developing optimal resourcing strategies, crafting frameworks for excellence, and analyzing engagement levels with KOLs, our study provides a roadmap for maximizing rare disease field medical impact in the APAC region.


KEY TOPICS

  • Effective Rare Disease Field Performance Metrics in the APAC Region
  • Building a Rare Disease Field Medical Excellence Framework
  • Target and Engagement Levels of Rare Disease KOLs in the APAC Region
  • Average Time Spent by Rare Disease MSLs on KOL Interactions and Internal Activities in the APAC Region
  • Rare Disease Field Medical Staffing Footprint in the APAC Region
  • Key Insights and Lessons Learned for Measuring the Impact of Rare Disease MSLs in the APAC Region

KEY METRICS

  • Asia-Pacific field scorecard: Benchmarking rare disease engagements
  • Average total panel size supported by an individual rare disease MSL in the APAC region
  • Average number of monthly KOL/HCP and F2F meetings in the APAC region – Rare disease segment
  • Value assigned to each interaction type on the rare disease MSL scorecard (APAC)
  • Engagement metrics for non-tiered rare disease KOLs in the APAC region
  • Average annual field presence of rare disease MSLs in the APAC region
  • Time spent by rare disease MSLs on external, internal, and logistics activities in the APAC region
  • Weekly rare disease MSL time allocation across activity streams in the APAC region
  • Rare disease MSL engagement mix in the APAC region
  • Rare disease field medical staffing footprint in the APAC region

SAMPLE KEY FINDINGS

  • Metrics for Engaging Non-Tiered Rare Disease KOLs in the APAC Region: Rare diseases manufacturers from the APAC region do not employ special metrics for measuring non-tiered KOL engagements. Meanwhile, across all therapeutic areas, 40% of companies employ special metrics to assess the engagement of non-tiered KOLs.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from rare disease companies around the world through a custom benchmark survey. Focused on rare disease field medical operations
in the APAC region, the research drew insights from a diverse range of respondents.

Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.